journal article·2020-05Open access

Polymeric Nanoparticles with Neglectable Protein Corona

Irina Alberg, Stefan Kramer, Meike Schinnerer, Qizhi Hu, Christine Seidl, Christian Leps, Natascha Drude, Diana Möckel, Cristianne Rijcken, Twan Lammers, Mustafa Diken, Michael Maskos, Svenja Morsbach, Katharina Landfester, Stefan Tenzer, Matthias Barz, Rudolf Zentel

Small· Volume 16· Issue 18

Abstract

Abstract The current understanding of nanoparticle–protein interactions indicates that they rapidly adsorb proteins upon introduction into a living organism. The formed protein corona determines thereafter identity and fate of nanoparticles in the body. The present study evaluates the protein affinity of three core‐crosslinked polymeric nanoparticles with long circulation times, differing in the hydrophilic polymer material forming the particle surface, namely poly(N‐2‐hydroxypropylmethacrylamide) (pHPMA), polysarcosine (pSar), and poly(ethylene glycol) (PEG). This includes the nanotherapeutic CPC634, which is currently in clinical phase II evaluation. To investigate possible protein corona formation, the nanoparticles are incubated in human blood plasma and separated by asymmetrical flow field‐flow fractionation (AF4). Notably, light scattering shows no detectable differences in particle size or polydispersity upon incubation with plasma for all nanoparticles, while in gel electrophoresis, minor amounts of proteins can be detected in the particle fraction. Label‐free quantitative proteomics is additionally applied to analyze and quantify the composition of the proteins. It proves that some proteins are enriched, but their concentration is significantly less than one protein per particle. Thus, most of the nanoparticles are not associated with any proteins. Therefore, this work underlines that polymeric nanoparticles can be synthesized, for which a protein corona formation does not take place.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Minerals Flotation and Separation Techniques · Field-Flow Fractionation Techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Organic Chemistry Johannes Gutenberg University Mainz Duesbergweg 10‐14 Mainz D‐55128 Germany

Institute of Physical Chemistry Johannes Gutenberg University Mainz Duesbergweg 10‐14 Mainz D‐55128 Germany

Cristal Therapeutics Oxfordlaan 55 Maastricht 6229 EV The Netherlands

Institute for Immunology University Medical Center of Mainz Langenbeckstr. 1 Mainz 55131 Germany

Department of Nanomedicine and Theranostics Institute for Experimental Molecular Imaging RWTH Aachen University Clinic Forckenbecktrasse 55 Aachen 52074 Germany

TRON ‐ Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH Freiligrathstr. 12 Mainz 55131 Germany

Fraunhofer Institute for Microengineering and Microsystems IMM Carl‐Zeiss‐Str. 18‐20 Mainz 55129 Germany

Max Planck Institute for Polymer Research Ackermannweg 10 Mainz 55128 Germany

Funding

Deutsche Forschungsgemeinschaft

References (75)

Show source-provided references
1. 10.1016/j.addr.2009.08.00110.1016/j.addr.2009.08.001 ↗
2. 10.1016/j.ijpharm.2016.10.01310.1016/j.ijpharm.2016.10.013 ↗
3. 10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
4. 10.1038/nbt.333010.1038/nbt.3330 ↗
5. 10.1016/j.cplett.2007.07.07510.1016/j.cplett.2007.07.075 ↗
6. 10.1073/pnas.060858210410.1073/pnas.0608582104 ↗
7. 10.1039/C7NR08322J10.1039/C7NR08322J ↗
8. 10.1038/s41467-017-00600-w10.1038/s41467-017-00600-w ↗
9. Hilla A. · RSC Adv. · 2010 · 8 · 4017
10. 10.1021/acs.biomac.5b0010810.1021/acs.biomac.5b00108 ↗
11. 10.1021/nl202940k10.1021/nl202940k ↗
12. 10.1038/ncomms1347510.1038/ncomms13475 ↗
13. 10.1038/ncomms1177010.1038/ncomms11770 ↗
14. 10.1021/ja406924v10.1021/ja406924v ↗
15. 10.1038/nnano.2012.23710.1038/nnano.2012.237 ↗
16. 10.1021/ja107583h10.1021/ja107583h ↗
17. 10.1016/j.nantod.2015.01.00510.1016/j.nantod.2015.01.005 ↗
18. 10.1039/C7NR09355A10.1039/C7NR09355A ↗
19. 10.1021/acs.biomac.9b0053910.1021/acs.biomac.9b00539 ↗
20. 10.1039/C7NR07450F10.1039/C7NR07450F ↗
21. 10.1016/j.biomaterials.2015.02.08510.1016/j.biomaterials.2015.02.085 ↗
22. 10.1039/9781788016452-0030810.1039/9781788016452-00308 ↗
23. 10.1039/C5NR02618K10.1039/C5NR02618K ↗
24. 10.1038/nprot.2014.13910.1038/nprot.2014.139 ↗
25. 10.1021/acsnano.5b0330010.1021/acsnano.5b03300 ↗
26. 10.1016/j.actbio.2018.05.05710.1016/j.actbio.2018.05.057 ↗
27. 10.1080/0149639660804943910.1080/01496396608049439 ↗
28. 10.1126/science.850299010.1126/science.8502990 ↗
29. 10.1016/j.progpolymsci.2008.11.00110.1016/j.progpolymsci.2008.11.001 ↗
30. 10.1016/j.aca.2013.11.02110.1016/j.aca.2013.11.021 ↗
31. 10.1002/anie.20190232310.1002/anie.201902323 ↗
32. 10.1016/j.jconrel.2016.07.01210.1016/j.jconrel.2016.07.012 ↗
33. 10.1002/marc.20100009010.1002/marc.201000090 ↗
34. 10.1002/mabi.20170020910.1002/mabi.201700209 ↗
35. 10.1016/j.polymer.2015.04.07010.1016/j.polymer.2015.04.070 ↗
36. 10.1021/acs.macromol.8b0025810.1021/acs.macromol.8b00258 ↗
37. 10.1016/j.jconrel.2012.03.02010.1016/j.jconrel.2012.03.020 ↗
38. Vasey P. A. · Clin. Cancer Res. · 1999 · 5 · 83
39. 10.1016/j.csbj.2018.10.01210.1016/j.csbj.2018.10.012 ↗
40. 10.1002/anie.20160223310.1002/anie.201602233 ↗
41. 10.2147/IJN.S12930010.2147/IJN.S129300 ↗
42. 10.1038/s41467-018-07755-010.1038/s41467-018-07755-0 ↗
43. 10.1021/la010384m10.1021/la010384m ↗
44. 10.1021/acs.macromol.8b0025810.1021/acs.macromol.8b00258 ↗
45. 10.1016/j.jconrel.2005.09.01010.1016/j.jconrel.2005.09.010 ↗
46. 10.1021/la103382j10.1021/la103382j ↗
47. Schäfer T. · 2019 · 63
48. 10.1002/macp.20170011310.1002/macp.201700113 ↗
49. 10.1021/ma502497x10.1021/ma502497x ↗
50. 10.1007/978-1-60327-198-110.1007/978-1-60327-198-1 ↗
51. 10.1016/j.jpba.2018.08.03510.1016/j.jpba.2018.08.035 ↗
52. 10.1200/JCO.2019.37.15_suppl.302610.1200/JCO.2019.37.15_suppl.3026 ↗
53. 10.1038/nnano.2013.18110.1038/nnano.2013.181 ↗
54. 10.1021/la401192x10.1021/la401192x ↗
55. 10.1021/bm100971q10.1021/bm100971q ↗
56. 10.1021/acs.molpharmaceut.8b0103310.1021/acs.molpharmaceut.8b01033 ↗
57. 10.1007/978-3-540-32910-710.1007/978-3-540-32910-7 ↗
58. 10.1038/nprot.2006.28810.1038/nprot.2006.288 ↗
59. 10.1021/acs.jproteome.7b0043310.1021/acs.jproteome.7b00433 ↗
60. 10.1002/adma.20180333510.1002/adma.201803335 ↗
61. 10.1002/smll.20130354010.1002/smll.201303540 ↗
62. 10.1021/nn500647810.1021/nn5006478 ↗
63. 10.1039/C7NR02977B10.1039/C7NR02977B ↗
64. 10.1021/acs.bioconjchem.8b0031910.1021/acs.bioconjchem.8b00319 ↗
65. 10.1002/marc.20160004610.1002/marc.201600046 ↗
66. 10.1021/acs.biomac.9b0086810.1021/acs.biomac.9b00868 ↗
67. 10.1007/s00216-019-01673-w10.1007/s00216-019-01673-w ↗
68. 10.1159/00010725110.1159/000107251 ↗
69. 10.1038/227680a010.1038/227680a0 ↗
70. 10.4172/2157-7439.100019310.4172/2157-7439.1000193 ↗
71. 10.1038/nprot.2016.04210.1038/nprot.2016.042 ↗
72. 10.1038/nmeth.276710.1038/nmeth.2767 ↗
73. 10.1074/mcp.M500230-MCP20010.1074/mcp.M500230-MCP200 ↗
74. 10.1007/978-1-4939-7493-1_710.1007/978-1-4939-7493-1_7 ↗
75. 10.1111/j.2517-6161.1995.tb02031.x10.1111/j.2517-6161.1995.tb02031.x ↗